Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumannii

To test the activity of a small molecule compound that targets Lipid II against Acinetobacter baumannii. Susceptibility to small molecule Lipid II inhibitor BAS00127538 was assessed using carbapenem- and colistin-resistant clinical isolates of A. baumannii. In addition, synergy between colisitin and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug design, development and therapy development and therapy, 2014-08, Vol.8 (default), p.1061-1064
1. Verfasser:	de Leeuw, Erik P H
Format:	Artikel
Sprache:	eng
Schlagworte:	Acinetobacter baumannii Acinetobacter baumannii - drug effects Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - pharmacology Antibiotics Antimicrobial agents Bacteria Bacterial infections Biosynthesis Carbapenems - pharmacology Clinical isolates Colistin Colistin - pharmacology drug development Drug resistance Drug Resistance, Multiple, Bacterial Drug Synergism FDA approval Gram-negative bacteria Indoles - administration & dosage Indoles - pharmacology Inhibitors Laboratories Lipid II Lipids Meningitis Methods Microbial Sensitivity Tests Multidrug resistance Nosocomial infections Pathogenesis Pneumonia Pyrans - administration & dosage Pyrans - pharmacology Rapid Communication Staphylococcus infections Uridine Diphosphate N-Acetylmuramic Acid - analogs & derivatives Uridine Diphosphate N-Acetylmuramic Acid - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To test the activity of a small molecule compound that targets Lipid II against Acinetobacter baumannii. Susceptibility to small molecule Lipid II inhibitor BAS00127538 was assessed using carbapenem- and colistin-resistant clinical isolates of A. baumannii. In addition, synergy between colisitin and this compound was assessed. Small molecule Lipid II inhibitor BAS00127538 potently acts against A. baumannii and acts synergistically with colistin. For the first time, a compound that targets Lipid II is described that acts against multi-drug resistant isolates of A. baumannii. The synergy with colistin warrants further lead development of BAS00127538.
ISSN:	1177-8881 1177-8881
DOI:	10.2147/DDDT.S68020